OXIRIS® HAEMOFILTER IN CRITICALLY ILL PATIENTS WITH SEPTIC SHOCK AND ACUTE KIDNEY INJURY: FIVE YEARS SINGLE-CENTER EXPERIENCE

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/9ccb166e8b91c857d244d1db0a721c1a.pdf

Abstract Title *

OXIRIS® HAEMOFILTER IN CRITICALLY ILL PATIENTS WITH SEPTIC SHOCK AND ACUTE KIDNEY INJURY: FIVE YEARS SINGLE-CENTER EXPERIENCE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Ziad Elhusseini zeyad_abdelgawad@hotmail.com Adan Hospital Medicine Ahmadi Kuwait *

Co-author 2

Reem Asad raasad@gmail.com Adan Hospital Medicine Ahmadi Kuwait -

Co-author 3

Mostafa Sallam Mostkimo2005@gmail.com Adan Hospital Medicine Ahmadi Kuwait -

Co-author 4

Ehab Nawar Dremntn90@gmail.com Adan Hospital Medicine Ahmadi Kuwait -

Co-author 5

Bassam Alhelal dr.alhelal@gmail.com Adan Hospital Medicine Ahmadi Kuwait -

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Septic shock remains a major cause of acute kidney injury (AKI) in critically ill patients, significantly contributing to both elevated mortality rates and long-term renal impairment among survivors. The oXiris® filter, an advanced modality of continuous renal replacement therapy (CRRT), not only provides renal support but also possesses the ability to adsorb endotoxins and clear inflammatory mediators. Current evidence continues to be variable when it comes to short and long term benefit in renal recovery.

Methods

We conducted a prospective observational study to evaluate the safety and efficacy of the oXiris® filter in patients with septic shock and AKI secondary to gram-negative infections undergoing CRRT. Demographic and clinical variables, as well as biochemical and hemodynamic markers, were assessed before and after treatment. Outcomes included changes in vasopressor requirements, inflammatory markers, serum lactate, mortality, and renal recovery at both ICU and hospital discharge. Patients with COVID-19 were excluded. CRRT with oXiris® was performed for 24–72 hours, with filter replacement every 24 hours or earlier if clotting occurred, before transitioning to the M100 filter (Baxter, USA).

Results

Sixty-six patients (mean age 53.7 ± 16.57) were enrolled from September 2018 to April 2024, with 63.6% males. After treatment, mean arterial pressure increased by 6.2%, and there were significant reductions in vasopressor usage, PCT, CRP, and serum lactate. ICU mortality was 50%, while kidney recovery was 44% at ICU discharge and 90% at hospital discharge

Conclusion

The application of the oXiris® filter in CRRT for up to 72 hours in patients with septic shock and AKI was associated with improved hemodynamic stability and favorable renal outcomes. These findings suggest potential survival and renal recovery benefits, warranting further multi-center trials to conclusively define both short- and long-term outcomes.

Kewords